Application of fenofibrate in preparation of medicine for promoting liver regeneration

By discovering fenofibrate in the liver resection mouse model to promote the enlargement and proliferation of liver cells, the problem of no effective drugs to regulate liver regeneration was solved, and the liver regeneration ability was significantly improved, providing clinical development of drugs to promote liver regeneration. Scientific basis.

CN118986954APending Publication Date: 2024-11-22SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410989473.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There is no effective drug that can regulate liver regeneration, improve liver regeneration after liver transplantation and resection, and in-depth study of the mechanism and targets of liver regeneration is of great clinical significance.

Method used

By establishing a mouse model of partial hepatic resection, it was found that fenofibrate can promote hepatocyte enlargement and proliferation, accelerate liver resuming, and promote liver regeneration, without significant pathological changes and inflammatory responses, and upregulate the expression of proliferation-related proteins.

Benefits of technology

Fenofibrate significantly increased the liver/weight ratio, and the liver/weight ratio increased significantly by 45.9% after 5 days of administration, providing a theoretical basis and scientific basis for the development of drugs to promote liver regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986954A_ABST
    Figure CN118986954A_ABST
Patent Text Reader

Abstract

The invention discloses an application of fenofibrate in promoting liver regeneration. By establishing a partial liver resection mouse model, it is found that fenofibrate can promote liver cell enlargement and liver cell proliferation of a mouse subjected to partial liver resection and accelerate liver weight recovery, the liver / body weight ratio is remarkably increased by 45.9% 5 days after administration, and then liver regeneration is promoted. The fenofibrate does not involve obvious pathological changes and inflammatory reactions in the process of promoting liver regeneration, and the fenofibrate can also up-regulate expression of proliferation-related proteins. The invention not only discloses a new application of fenofibrate in promoting liver regeneration after partial hepatic resection, but also provides a theoretical basis and a scientific basis for subsequent clinical development of an intervention strategy for promoting liver regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to the application of fenofibrate in the preparation of a drug for promoting liver regeneration. Background Art

[0002] Liver disease has become the fifth leading cause of death worldwide. Living donor liver transplantation and partial liver resection are the most commonly used and effective treatments for end-stage liver cancer, cirrhosis and other liver diseases. The powerful regenerative capacity of the liver is the basis for the clinical implementation of liver transplantation and resection, but the poor regenerative capacity of the residual liver often leads to severe liver failure after surgery in patients with liver disease, and ultimately leads to death. Currently, there are no effective intervention drugs to regulate liver regeneration. It is of great clinical significance to conduct in-depth research on the mechanisms and targets of liver regeneration, explore new treatment strategies, and improve the regenerative capacity of the liver after liver transplantation and resection.

[0003] Fenofibrate is a commonly used lipid-lowering drug in clinical practice, but its pharmacological effects are not limited to lipid regulation. Studies have found that fenofibrate can regulate liver glucose and bile acid homeostasis, reduce liver oxidative stress and inflammatory response, and has potential application value in the treatment of liver diseases. In animal model studies, fenofibrate also showed therapeutic effects on liver fibrosis and drug-induced liver injury. However, there are currently no reports on the effects and regulatory mechanisms of fenofibrate on liver regeneration. Summary of the invention

[0004] The present invention aims at the shortcomings and deficiencies of the prior art and provides a new application of fenofibrate in promoting liver regeneration.

[0005] The first object of the present invention is to provide the use of fenofibrate in preparing a drug for promoting liver regeneration.

[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0007] The present invention established a partial hepatectomy mouse model, and through immunohistochemical staining and Western blot analysis, it was found that fenofibrate can promote hepatocyte enlargement and hepatocyte proliferation in mice after partial hepatectomy, accelerate liver weight recovery, and further promote liver regeneration.

[0008] Therefore, the present invention requests protection for the following contents:

[0009] Application of fenofibrate in the preparation of drugs for promoting liver regeneration.

[0010] Specifically, the drug for promoting liver regeneration refers to a drug that can enhance the proliferation ability of hepatocytes.

[0011] Specifically, the drug for promoting liver regeneration refers to a drug that can improve the ability to restore the liver / body weight ratio.

[0012] Specifically, the drug for promoting liver regeneration refers to a drug that can promote liver regeneration after liver resection.

[0013] Based on this, drugs containing fenofibrate that promote liver regeneration can be developed.

[0014] Specifically, the drug can be used in combination with other drugs to prepare a compound pharmaceutical preparation.

[0015] Specifically, the drug also includes pharmaceutically acceptable salts of fenofibrate and its analogs.

[0016] The pharmaceutically acceptable salt is a sodium salt, a potassium salt or a calcium salt.

[0017] Fenofibrate sodium, fenofibrate potassium, fenofibrate calcium These salt forms may improve the pharmacokinetic properties of fenofibrate by changing its solubility, stability, and absorption characteristics. This makes the drug more effective in the body or more easily absorbed and utilized by the patient's body.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The present invention establishes a partial hepatectomy mouse model and finds that fenofibrate can promote liver cell enlargement and proliferation in mice after partial hepatectomy, accelerate liver weight recovery, and significantly increase the liver / body weight ratio by 45.9% after 5 days of administration, thereby promoting liver regeneration. Fenofibrate does not involve obvious pathological changes and inflammatory reactions in the process of promoting liver regeneration, and can also upregulate the expression of proliferation-related proteins (CCNA1, CCND1 and CCNE1). It provides a theoretical basis and scientific basis for the subsequent clinical development of drugs to promote liver regeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The figure shows that fenofibrate promotes liver regeneration after hepatectomy in C57BL / 6 mice, where A is the animal experiment plan; B is the liver weight ratio (n=5); C is a photo of the liver; the results are expressed as mean ± standard error, compared with the control group, ** represents P<0.01, **** represents P<0.0001.

[0021] Figure 2The figures show that fenofibrate did not cause obvious liver damage in C57BL / 6 mice after hepatectomy, among which, Figure A is H&E staining; Figure B is serum ALT, AST and ALP levels (n=5); Figure C is the mRNA levels of inflammatory factors Il-6 and Tnfa (n=3); the results are expressed as mean ± standard error, compared with the control group, ns=no significant difference, *** represents P<0.001, Scale bar=50μm.

[0022] Figure 3 The figures show that fenofibrate promotes the enlargement and proliferation of hepatocytes in mice after hepatectomy, among which, Figure A shows the immunohistochemical staining of CTNNB1 in the CV region and KI67 in the PV region; Figure B shows the quantification of cell size and the proportion of KI67-positive cells (n=3); Figure C shows the immunohistochemical staining of CTNNB1 in the PV region and KI67 in the CV region; the results are expressed as mean ± standard error, compared with the control group, * represents P < 0.05, ** represents P < 0.01, Scale bar = 50μm.

[0023] Figure 4 The figure shows that fenofibrate up-regulates the expression of proliferation-related proteins in wild-type mice after liver resection, wherein Figure A shows the expression levels of proliferation-related proteins CCNA1, CCND1 and CCNE1; Figure B shows protein quantification (n=3); the results are expressed as mean±standard error, compared with the control group, ns=no significant difference, *P<0.05, **P<0.01, ***P<0.001. DETAILED DESCRIPTION

[0024] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0025] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0026] Example 1 Animal Experiment Protocol

[0027] 1. Experimental animals: C57BL / 6 male mice, 7-8 weeks old, 22-25 g / mouse. Source: Guangdong Medical Experimental Animal Center SYXK (Yue) 2022-0002.

[0028] 2. Preparation of fenofibrate solution: accurately weigh 250 mg of fenofibrate, use corn oil as solvent, and prepare fenofibrate solutions with concentrations of 10 mg / mL, 5 mg / mL, and 2.5 mg / mL. Vortex for 30 seconds and sonicate for 15 minutes before use. The remaining solution should be stored in a refrigerator at 4°C.

[0029] 3. Procedures for partial liver resection in mice:

[0030] Experimental mice (C57BL / 6 mice) will be fasted for at least 12 hours before surgery, but will be allowed to drink water. The surgical area will be shaved and thoroughly disinfected to ensure sterile conditions during the surgical procedure.

[0031] Disinfection method: First, use a small electric razor or scissors to carefully remove the mouse hair in the surgical area. The shaving range should include the planned surgical area and the area around it of approximately 1-2 cm. Then, gently wipe the surgical area with sterile saline or 70% alcohol cotton balls to remove dirt and loose hair on the skin surface, and then wipe the surgical area twice again with 70% alcohol cotton balls to ensure that the skin is fully infiltrated; then, use iodine-containing disinfectant (such as povidone iodine) to wipe the surgical area three times, and wait for the skin surface to dry naturally after each wipe; finally, wipe the surgical area with 70% alcohol cotton balls to remove excess iodine. After shaving and disinfection, carefully lay sterile surgical towels to ensure that the surgical area and surgical tools are always in a sterile state. Surgical personnel should wear sterile gloves and thoroughly wash and disinfect their hands and arms before operation.

[0032] C57BL / 6 mice are generally anesthetized by intraperitoneal injection of an appropriate amount of anesthetic (e.g., pentobarbital hydrochloride) to ensure that they do not feel pain and discomfort during the operation. After ensuring the appropriate depth of anesthesia, a small incision is made along the midline of the mouse's abdomen to carefully expose the liver. 2 / 3 partial hepatectomy usually involves the removal of the left lateral lobe, left internal lobe, and right internal lobe. The left lateral lobe is removed first, followed by the left internal lobe, and finally the larger part of the right internal lobe. During the resection, delicate operation is required to avoid excessive bleeding, and hemostatic agents (such as coagulants or electrocoagulation) should be used to treat the broken blood vessels. After confirming that there is no active bleeding in the resection area, the abdominal wall is carefully sutured with absorbable suture material. After completing the operation, C57BL / 6 mice are placed in a constant temperature, quiet and clean environment to promote recovery.

[0033] IV. Drug administration and sampling in hepatectomized mice:

[0034] Fenofibrate was administered to C57BL / 6 mice after partial hepatectomy to investigate the promoting effect of fenofibrate on liver regeneration. The specific experimental groups are shown in Table 1 below:

[0035] Table 1 Experimental components of partial liver resection C57BL / 6 mice

[0036]

[0037] Samples were collected 24 hours after the last administration. The mice were weighed and their weights were recorded. Appropriate anesthesia was used to render the mice unconscious. The mice were killed by cervical dislocation. Blood was collected from the eye sockets at the same time. After standing for 30 minutes, the blood samples were centrifuged to separate the serum, which was then dispensed into clearly labeled EP tubes. All samples were immediately placed in pre-labeled low-temperature EP storage tubes and quickly transferred to an ultra-low temperature freezer at -80°C for subsequent biochemical analysis and molecular biology testing.

[0038] V. Experimental Results:

[0039] C57BL / 6 mice underwent 2 / 3 partial hepatectomy and were given fenofibrate at 50 mg / kg / day for 2 or 5 consecutive days after surgery (e.g. Figure 1 The results of the liver weight ratio of mice before and after administration are shown in Figure A. Figure 1 As shown in Figure B, 2 or 5 days after administration of fenofibrate, the liver / body weight ratio (liver / body weight ratio = (regenerated liver weight / postoperative body weight) × 100%) of the mice in the treatment group increased significantly (2 days, +17.8%; 5 days, +45.9%) compared with the control group, and the liver volume also increased significantly (as shown in Figure 2). Figure 1 (as shown in Figure C).

[0040] Example 2 Immunohistochemical staining analysis

[0041] 1. Experimental steps:

[0042] 1. Dewaxing and rehydration: Soak the liver tissue paraffin sections of the four groups of treated mice (Example 1) in cylinder No. 1 (xylene solution, 5 min), cylinder No. 2 (xylene solution, 5 min), cylinder No. 3 (xylene solution, 5 min), cylinder No. 4 (50% xylene / 50% anhydrous ethanol solution, 1 min), cylinder No. 5 (anhydrous ethanol, 1 min), cylinder No. 6 (anhydrous ethanol, 1 min), cylinder No. 7 (95% anhydrous ethanol, 2 min), cylinder No. 8 (80% anhydrous ethanol, 2 min) and cylinder No. 9 (70% anhydrous ethanol, 2 min). After soaking, take out the paraffin sections and rinse with running water. Wash the sections with PBS solution 3 times, 3 min each time.

[0043] 2. Antigen repair: Soak the slices in citrate buffer and heat in a microwave oven. First adjust to medium-high heat, then adjust to medium-low heat after boiling, and heat for 11 minutes. Take out the solution tank, let it cool, then take out the slices and soak them in PBS solution for 3 minutes.

[0044] 3. Quenching of endogenous peroxidase: Use an immunohistochemistry pen to draw a circle around the slice tissue, and add 3% hydrogen peroxide solution to the circled area. After incubation for 15 minutes, take out the slice and soak it in PBS solution for 3 minutes.

[0045] 4. Blocking: Add 10% goat serum to the circled area and incubate at room temperature for 60 minutes.

[0046] 5. Primary antibody incubation: Add KI67 or CTNNB1 primary antibody working solution and incubate overnight at 4°C.

[0047] 6. Secondary antibody incubation: The next day, transfer the wet box to a 37°C incubator and incubate for 30 minutes. Soak in PBS solution 3 times, 5 minutes each time. Wipe off the PBS solution, add mouse or rabbit secondary antibody solution, and continue incubation at room temperature for 60 minutes. After incubation, soak in PBS solution 3 times, 5 minutes each time.

[0048] 7. Diaminobenzidine (DAB) staining: Add DAB working solution to the tissue area of ​​the slice. Observe under the microscope. When the staining is moderate, soak the slice in ultrapure water to stop the staining.

[0049] 8. Hematoxylin-eosin staining: Soak the sections in a hematoxylin dye tank for 3 minutes and rinse with running water until the color of the dye disappears.

[0050] 9. Dedifferentiation and blueing: Soak in 1% hydrochloric acid alcohol for 3-5 seconds, rinse with running water, soak in 1% ammonia water for 3 minutes, rinse with running water until there is no odor.

[0051] 10. Dehydration and sealing: In contrast to the dewaxing and rehydration steps, immerse the sections in the order of No. 9 cylinder (70% anhydrous ethanol, 2 min), No. 8 cylinder (80% anhydrous ethanol, 2 min), No. 7 cylinder (95% anhydrous ethanol, 2 min), No. 6 cylinder (anhydrous ethanol, 1 min), No. 5 cylinder (anhydrous ethanol, 1 min), No. 4 cylinder (50% xylene / 50% anhydrous ethanol solution, 1 min), No. 3 cylinder (xylene solution, 5 min), No. 2 cylinder (xylene solution, 5 min) and No. 1 cylinder (xylene solution, 5 min). After sealing and drying, analyze under a microscope.

[0052] 2. Experimental results:

[0053] Observe the results of hematoxylin-eosin (H&E) staining of liver tissue. Figure 2 As shown in Figure A. Figure 2 As shown in Figure A, compared with the control group, no abnormal damage areas were found in the liver tissue of mice treated with Norfibrate for 2 and 5 days. Figure 2 As shown in Figure B. Figure 2 As shown in Figure B, there was no significant change in the serum ALT and AST levels of mice before and after the administration of fenofibrate. The serum ALP of mice given fenofibrate for 2 days after surgery decreased significantly. There was no significant difference in the serum ALP of mice given fenofibrate for 5 days after surgery compared with the control group. Figure 2 As shown in Figure C. Figure 2 As shown in Figure C, there was no significant change in the mRNA expression levels of inflammation-related genes Tnfa and Il-6 before and after fenofibrate administration. The above results indicate that fenofibrate promotes liver regeneration in mice without involving obvious pathological changes and inflammatory responses, suggesting that fenofibrate can promote liver regeneration after partial hepatectomy in mice.

[0054] CTNNB1 and KI67 staining were used to outline the hepatocytes and mark the proliferating cells, respectively, to further investigate the effects of fenofibrate on the volume and proliferation of hepatocytes.

[0055] The results of CTNNB1 staining in the CV region are as follows Figure 3 As shown in Figure A, 2 days after fenofibrate administration, the 2 ), the size of the CV region cells in the liver of the mice in the drug group increased significantly (+13.3%), and 5 days after the operation, the size of the CV region cells in the liver of the mice in the drug group increased significantly (+13.3%), compared with the control group (451.1±17.2μm 2 ), the size of cells in the CV region of the liver of the mice in the drug-treated group increased significantly (+12.7%); the results of CTNNB1 staining in the PV region were as follows Figure 3 As shown in Figure C, the size of cells in the PV region did not change significantly before and after the administration of fenofibrate.

[0056] The results of KI67 staining in the CV region are as follows Figure 3 As shown in Figure C, KI67 in the CV region before and after administration of fenofibrate + There was no significant change in the cell ratio. Figure 3 As shown in Figure A, 2 days after the operation, fenofibrate was administered to mice in the treatment group (15.6%). + The proportion of KI67 cells in the treated group increased significantly (+41.7%). Five days after the operation, the fenofibrate was given to the mice in the treated group, compared with the control group (5.3%). + The cell ratio increased significantly (+105.7%).

[0057] These results suggest that fenofibrate can promote the enlargement of CV hepatocytes and the proliferation of PV hepatocytes, thereby promoting the process of liver regeneration.

[0058] Example 3 Western blot

[0059] 1. Experimental steps:

[0060] 1. Protein sample preparation: Add 2 ceramic beads and about 50 mg of liver tissue to the homogenizer tube in advance, add 500 μL of protein lysis solution (PMSF: RIPA = 1: 100) to each tube, and shake up and down to immerse the tissue in the lysis solution. Use the 5000-2×8-10 program in the homogenizer (the homogenizer is performed twice at a speed of 5000 rpm, each homogenization operation time is 8 seconds, and there is a 10-second interval between the two homogenizations) to lyse the cells. Pipette the homogenate into a 1.5 mL EP tube, centrifuge at 4°C, 16000g for 30 minutes, and take the supernatant as the required protein solution. Pipette 25 μL of the supernatant into 725 μL PBS and dilute 30 times for BCA protein quantification. Mix solution A and solution B in the BCA kit (solution A: solution B = 50: 1). Take out the 96-well plate, add 200 μL of the mixed solution to each well, and then add 25 μL of the diluted protein solution. After incubation at 37°C for 30 min, the absorbance value was detected and the protein concentration was calculated. According to the calculated protein sample concentration, PBS and 5× bromophenol blue loading buffer were added, vortexed and mixed thoroughly, centrifuged instantaneously, heated at 100°C for 10 min in a dry thermostat for heat denaturation, and stored in a -80°C refrigerator for later use.

[0061] 2. SDS-PAGE polyacrylamide gel electrophoresis

[0062] (1) Preparation of gel: Prepare a gel solution containing 10% polyacrylamide as the separation gel (see Table 2 below), and add the gel solution to the glass plate. Add about 300 μL of isopropanol solution to flatten the surface of the separation gel. Let it stand at room temperature for about 30 minutes until the separation gel solidifies. Discard the excess isopropanol solution, prepare the concentrated gel (see Table 3 below), add the gel solution to the glass plate, and insert the sample comb. Let it stand at room temperature for about 30 minutes until the concentrated gel solidifies.

[0063] Table 2 10% separation gel formula

[0064]

[0065] Table 3 5% concentrated gel formula

[0066]

[0067] (2) Sample loading: Vortex the sample (Example 3 (1)) and place it in a dry thermostat and heat it at 100°C for 5 min. Remove the gel plate and install the electrophoresis device. Remove the comb and use a pipette to gently blow the channels to blow away the broken gel. Add 20 μL of protein sample or 4 μL of protein labeling buffer to the corresponding lane.

[0068] (3) Electrophoresis: Set the electrophoresis conditions to a constant voltage of 75 V for 30 min and 125 V for 60 min.

[0069] 3. Transfer: Cut the 0.45μm polyvinylidene fluoride (PVDF) membrane into appropriate size and soak it in methanol solution for activation for about 30s. Place the membrane in the corresponding position of the gel, cut the gel block and place it on the electrotransfer clamp, sponge and filter paper, then cover the gel block with filter paper and sponge in turn, and clamp the electrotransfer clamp. Constant current 230mA, transfer time is set according to protein size.

[0070] 4. Blocking and hybridization: After electrotransfer, take out the membrane and soak it in 5% protein blocking solution, shaking slowly at room temperature for 60 minutes. After blocking, incubate the membrane with the corresponding primary antibody solution overnight. The next day, wash the membrane 3 times with Tris-Hcl buffer (TBST) and incubate the membrane with mouse or rabbit secondary antibody solution at room temperature for 60 minutes. After the secondary antibody incubation, wash the membrane 3 times with TBST.

[0071] 5. Development: Mix luminescent liquid A and liquid B in a volume ratio of 1:1, wipe the liquid on the surface of the membrane with filter paper, incubate with the mixed luminescent liquid for a certain period of time, expose and image in a developer, and save the results.

[0072] 2. Experimental results:

[0073] Fenofibrate was administered to mice after partial hepatectomy for 2 or 5 days. Fenofibrate upregulated the expression of proliferation-related proteins in wild-type mice after hepatectomy. Figure 4 As shown. Figure 4 It can be seen that after 2 days of administration, proliferation-related proteins CCNA1 and CCND1 were significantly upregulated (CCNA1: +367.1%, ***P<0.001; CCND1: +50.0%, **P<0.01). After 5 days of administration, proliferation-related proteins CCNA1, CCND1 and CCNE1 were all significantly upregulated (CCNA1: +95.9%, ***P<0.001; CCND1: +80.5%, **P<0.01; CCNE1: +170.9%, *P<0.05). The above results suggest that fenofibrate can upregulate the expression of proliferation-related proteins and promote hepatocyte proliferation in the process of promoting liver regeneration.

[0074] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Application of fenofibrate in the preparation of drugs for promoting liver regeneration.

2. The use according to claim 1, characterized in that: The drug for promoting liver regeneration refers to a drug that can enhance the proliferation ability of liver cells.

3. The use according to claim 1, characterized in that: The liver regeneration promoting drug refers to a drug that can promote the restoration of the liver / body weight ratio.

4. The use according to claim 1, characterized in that: The drug for promoting liver regeneration refers to a drug that can promote liver regeneration after liver resection.

5. The use according to claim 1, characterized in that: The liver regeneration promoting drug refers to a drug that can upregulate the expression of proliferation-related proteins.

6. The use according to claim 5, characterized in that: The proliferation-related protein is CCNA1.

7. The use according to claim 5, characterized in that: The proliferation-related protein is CCND1.

8. The use according to claim 5, characterized in that: The proliferation-related protein is CCNE1.

9. The use according to any one of claims 1 to 5, characterized in that: The drug includes fenofibrate or a pharmaceutically acceptable salt thereof, and also includes a pharmaceutically acceptable carrier.

10. The use according to claim 9, characterized in that: The pharmaceutically acceptable salt is a sodium salt, a potassium salt or a calcium salt.